Invivyd (IVVD) Total Current Liabilities (2020 - 2025)
Invivyd (IVVD) reported Total Current Liabilities of $34.2 million for Q4 2025, down 44.88% on a YoY basis from $62.0 million in Q4 2024, and down 23.22% quarter-over-quarter from $44.5 million in Q3 2025.
Invivyd (IVVD) Total Current Liabilities (2020 - 2025) Analysis & Trends
Invivyd has reported Total Current Liabilities for 6 years, with the latest figure at $34.2 million in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities fell 44.88% year-over-year to $34.2 million; the trailing twelve-month figure through Dec 2025 stood at $34.2 million (down 44.88% YoY), and the FY2025 full-year result was $34.2 million, down 44.88% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $34.2 million, down from $44.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $95.5 million in Q1 2022, with the low at $22.1 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $47.7 million across 5 years, with a median of $44.5 million in 2025.
- Annual changes were most pronounced in 2021 — Total Current Liabilities surged 374.76% — and 2023, when it tumbled 76.91%.
- Invivyd's Total Current Liabilities stood at $62.1 million in 2021, then sank by 59.67% to $25.0 million in 2022, then jumped by 100.91% to $50.3 million in 2023, then increased by 23.23% to $62.0 million in 2024, then tumbled by 44.88% to $34.2 million in 2025.
- The last three Total Current Liabilities figures came in at $34.2 million (Q4 2025), $44.5 million (Q3 2025), and $44.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | 34.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.16 Mn |
| Sep 30, 2025 | 44.50 Mn |
| Jun 30, 2025 | 44.45 Mn |
| Mar 31, 2025 | 49.60 Mn |
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.54 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.35 Mn |
| Dec 31, 2023 | 50.29 Mn |
| Sep 30, 2023 | 26.79 Mn |
| Jun 30, 2023 | 32.51 Mn |
| Mar 31, 2023 | 22.06 Mn |
| Dec 31, 2022 | 25.03 Mn |
| Sep 30, 2022 | 46.13 Mn |
| Jun 30, 2022 | 67.88 Mn |
| Mar 31, 2022 | 95.53 Mn |
| Dec 31, 2021 | 62.06 Mn |
| Sep 30, 2021 | 53.05 Mn |
| Jun 30, 2021 | 37.90 Mn |
| Dec 31, 2020 | 13.07 Mn |